The microbiome and gynaecological cancer development, prevention and therapy
- 18 February 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Urology
- Vol. 17 (4), 232-250
- https://doi.org/10.1038/s41585-020-0286-z
Abstract
The female reproductive tract (FRT), similar to other mucosal sites, harbours a site-specific microbiome, which has an essential role in maintaining health and homeostasis. In the majority of women of reproductive age, the microbiota of the lower FRT (vagina and cervix) microenvironment is dominated by Lactobacillus species, which benefit the host through symbiotic relationships. By contrast, the upper FRT (uterus, Fallopian tubes and ovaries) might be sterile in healthy individuals or contain a low-biomass microbiome with a diverse mixture of microorganisms. When dysbiosis occurs, altered immune and metabolic signalling can affect hallmarks of cancer, including chronic inflammation, epithelial barrier breach, changes in cellular proliferation and apoptosis, genome instability, angiogenesis and metabolic dysregulation. These pathophysiological changes might lead to gynaecological cancer. Emerging evidence shows that genital dysbiosis and/or specific bacteria might have an active role in the development and/or progression and metastasis of gynaecological malignancies, such as cervical, endometrial and ovarian cancers, through direct and indirect mechanisms, including modulation of oestrogen metabolism. Cancer therapies might also alter microbiota at sites throughout the body. Reciprocally, microbiota composition can influence the efficacy and toxic effects of cancer therapies, as well as quality of life following cancer treatment. Modulation of the microbiome via probiotics or microbiota transplant might prove useful in improving responsiveness to cancer treatment and quality of life. Elucidating these complex host–microbiome interactions, including the crosstalk between distal and local sites, will translate into interventions for prevention, therapeutic efficacy and toxic effects to enhance health outcomes for women with gynaecological cancers.This publication has 224 references indexed in Scilit:
- Comparison of the vaginal microbiota diversity of women with and without human papillomavirus infection: a cross-sectional studyBMC Infectious Diseases, 2013
- Association of the Vaginal Microbiota with Human Papillomavirus Infection in a Korean Twin CohortPLOS ONE, 2013
- Structure, function and diversity of the healthy human microbiomeNature, 2012
- A discrete population of squamocolumnar junction cells implicated in the pathogenesis of cervical cancerProceedings of the National Academy of Sciences of the United States of America, 2012
- Effects of Bacterial Vaginosis-Associated Bacteria and Sexual Intercourse on Vaginal Colonization With the Probiotic Lactobacillus crispatus CTV-05Sexually Transmitted Diseases, 2011
- Microbiome and MalignancyCell Host & Microbe, 2011
- Randomized, Placebo-Controlled Phase 2 Trial of a Lactobacillus crispatus Probiotic Given Intravaginally for Prevention of Recurrent Urinary Tract InfectionClinical Infectious Diseases, 2011
- Vaginal microbiome of reproductive-age womenProceedings of the National Academy of Sciences of the United States of America, 2010
- A Longitudinal Study of Vaginal Douching and Bacterial Vaginosis--A Marginal Structural Modeling AnalysisAmerican Journal of Epidemiology, 2008
- Metagenomic Analysis of the Human Distal Gut MicrobiomeScience, 2006